Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, stem-cell technology specialist Cytori Therapeutics (NASDAQ:CYTX) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Cytori's business and see what CAPS investors are saying about the stock right now.

Cytori facts

Headquarters (Founded)

San Diego (1996)

Market Cap

$191.4 million



Trailing-12-Month Revenue

$14 million


Co-Founder/CEO Christopher Calhoun
CFO Mark Saad

Compound Annual Revenue Growth (Over Past 3 Years)



$13.14 million / $6 million


Stryker (NYSE:SYK)
Medtronic (NYSE:MDT)

CAPS Members Bullish on CYTX Also Bullish on

Bank of America (NYSE:BAC)

CAPS Members Bearish on CYTX Also Bearish on

Exelixis (NASDAQ:EXEL)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 93% of the 136 members who have rated Cytori believe the stock will outperform the S&P 500 going forward. These bulls include gokylego and All-Star mrindependent, who is ranked in the top 2% of our community.

Earlier this year, gokylego nicely explained where all the excitement stems from:

[Cytori] has a great product that is used for natural tissue regeneration from the patients own body. Using adipose stem cells, doctors may harvest patients own tissue instead of using controversial embryonic stem cells. [Cytori] has big investment from [Olympus Corp.] as well as distribution deals in Europe and the US with [General Electric (NYSE:GE)].

In a pitch from two days ago, mrindependent also helped Fools follow the Cytori story. Here's an excerpt:

Cytori makes products focused on the extraction of stem cells from body fat cells, reconstitution of the cells in a proprietary machine, and then their use in heart surgery and reconstructive breast surgery. Cytori's researchers have had a lot of success in using a patient's own cells as grafts in these very important applications with huge end markets. ... [Cytori's] current market cap is only $193 million. Obviously, the company is worth billions if its breast reconstruction and heart surgery products continue to succeed.

What do you think about Cytori, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. The CAPS community is waiting to hear your opinions. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Stryker is a Motley Fool Inside Value pick, and the Fool owns shares. The Fool owns shares of Medtronic. Exelixis is a recommendation of Rule Breakers, and the Fool owns shares of that, too. The Fool's disclosure policy always gets a perfect score.